BioSpace News Archive

Arcutis Biotherapeutics, Inc. announced the closing of its previously announced underwritten public offering of 18,157,895 shares of common stock at a public offering price of $9.50 per share, which includes 2,368,421 shares issued upon the exercise in full by the underwriters of their option to purchase additional shares of common stock at the public offering price, less underwriting discounts and commissions.

Cara Therapeutics, Inc. (Nasdaq: CARA), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced financial results and operational highlights for the fourth quarter and full year ended December 31, 2023.

Poseida Therapeutics, Inc., a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, announced that the Compensation Committee of its Board of Directors granted an inducement award to an employee.

Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”) today announced that it has entered into a secured credit agreement with Innoviva Strategic Opportunities LLC, a wholly-owned subsidiary of Innoviva, Inc. (Nasdaq: INVA) (collectively, “Innoviva”), Armata’s largest shareholder.

Sonendo, Inc., a leading dental technology company and developer of the GentleWave® System, announced that it has executed a definitive agreement for the sale of its Software Segment assets comprised of TDO Software, to Valsoft Corporation Inc., a Quebec company based in Montreal specializing in the acquisition and development of vertical market software businesses.

Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (NYSE: RBOT, RBOT WS), a next-generation robotics technology company seeking to improve patient outcomes as well as both the cost and efficiency of surgical procedures, today announced financial results for the quarter and full year ended December 31, 2023.

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, announced that it has commenced an underwritten public offering of $250 million of shares of its common stock.

Verona Pharma plc, announces Mr. Andrew Fisher has joined the Company as General Counsel, and member of the Executive Management Team.

CytoMed Therapeutics Limited announced that it has entered into a Research Collaboration Agreement with Sengkang General Hospital Pte Ltd, a public hospital in Singapore and a member of the SingHealth group to establish proof-of-concept use of an injectable cartilage regeneration therapy that has been developed with donor-sourced, umbilical cord-derived mesenchymal stem cells to treat cartilage injury.

SOLASCURE Ltd has announced the publication of its CLEANVLU Phase IIa clinical trial report in the International Wound Journal, a leading wound care journal.1 SolasCure’s first investigational product, Aurase Wound Gel, is a hydrogel releasing tarumase, a recombinant enzyme derived from medical maggots, which aims to promote wound healing through debridement and wound bed preparation.